Mediwound Company Insiders
| MDWD Stock | USD 16.98 0.37 2.23% |
Mediwound employs about 121 people. The company is managed by 13 executives with a total tenure of roughly 283 years. For Mediwound, management analysis helps investors assess whether leadership decisions support the broader investment thesis or introduce new operating risk. That matters because management quality often influences how well a company responds when business conditions become less favorable.
Mediwound | Build portfolio with Mediwound Stock |
Mediwound's Workforce Through the Years
Historical employee data for Mediwound can give investors another way to assess whether the business is scaling, restructuring, or stabilizing across different operating conditions. Current projections suggest a workforce around about 120 employees by April 2026, which should be reviewed alongside revenue and margin trends.Macro event markers
Management Team Effectiveness
The company has return on total asset (ROA) of -19.77 % which means that for every $100 of assets, it generated a loss of $19.77. This is well below the sector average. Similarly, it shows a return on stockholder's equity (ROE) of -63.86 %, which implies that it generated no returns to current stockholders.As of the most recent trading session, Common Stock Shares Outstanding is projected to grow to approximately 11.9 M, while Net Loss are moving lower toward about -18.5 M.
Stock Institutional Investors
Institutions hold about 56.99% of Mediwound while insiders own roughly 15.84%. Current market capitalization is about 216.83 Million. At that level, both institutional and retail traders shape the daily action. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. Watching turnover and volume trends alongside ownership data adds depth to the picture.
| Shares | State Street Corp | 2025-09-30 | 112.4 K | Ark Investment Management Llc | 2025-12-31 | 106.4 K | Millennium Management Llc | 2025-12-31 | 102.1 K | Citadel Advisors Llc | 2025-12-31 | 89.6 K | Ubs Group Ag | 2025-09-30 | 76.3 K | Clal Insurance Enterprises Holdings Ltd | 2025-12-31 | 71 K | Vanguard Group Inc | 2025-12-31 | 65.3 K | Menora Mivtachim Holdings Limited | 2025-12-31 | 65.1 K | Sargent Investment Group, Llc | 2025-12-31 | 59.9 K | Investors Finance Co Plc | 2025-12-31 | 872.1 K | Yelin Lapidot Holdings Management Ltd | 2025-12-31 | 763.1 K |
Insider Trading Activities
Insider disclosures for Mediwound show how people closest to the business are behaving as market expectations change. The pattern is most useful when compared with earnings releases and guidance changes rather than treated alone.
Shamir Nachum six days ago Insider Trading |
Outstanding Bonds
Mediwound may use bonds as part of its capital structure to fund operations, refinance liabilities, or support acquisitions and other long-duration investments. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Corporate Filings
F3 | 18th of March 2026 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
6K | 5th of March 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 19th of February 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 17th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 11th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 5th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
6K | 15th of January 2026 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Shares in Circulation | First Issued 2012-12-31 | Previous Quarter 11 M | Current Value 12.8 M | Average Shares Outstanding 5.1 M | Quarterly Volatility 2.9 M |
Macro event markers
Holders Distribution
For Mediwound, institutional participation can be supportive or destabilizing depending on whether large holders are building conviction or reducing exposure. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Market Cap and Value
Workforce Comparison
Mediwound holds the #2 position for number of employees relative to top peers. The total workforce of Health Care industry is now estimated at about 629. Mediwound retains roughly 121 in number of employees claiming about 19% of equities under Health Care sector.
The company has Profit Margin (PM) of -1.41 %, which may indicate that the company does not effectively execute on its pricing strategies. This is well below the sector average. Similarly, it shows Operating Margin (OM) of -4.18 %, which signifies that for every $100 of sales, the company has a net operating loss of $4.18. Insider Trading History
The buy-sell ratio in Mediwound's insider history separates pay-related activity from trades based on conviction. Shares outstanding are near 12.8 M. Since insider trades are publicly filed, the record helps verify whether management actions match their words.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold |
|---|
Notable Stakeholders
Stakeholders matter for Mediwound because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Lior MD | CoFounder | Profile | |
| Shmulik Hess | COO Officer | Profile | |
| Hagit Mashiach | VP Resources | Profile | |
| Yaron Adv | General VP | Profile | |
| CPA CPA | Ex Director | Profile | |
| Hani Luxenburg | Chief Officer | Profile | |
| Pr MD | CoFounder Director | Profile | |
| Ety MBA | Chief Officer | Profile | |
| Ofer BSc | Chief Officer | Profile | |
| CWS DPM | Chief Officer | Profile | |
| Ety Klinger | Chief Officer | Profile | |
| Liron Gal | Executive Technology | Profile | |
| Barry Wolfenson | Executive Development | Profile |
Management Information & Data Sources
Mediwound is a micro-cap company across Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Management effectiveness is reflected in operating results, capital allocation choices, and margin durability. Management quality is most visible when paired with profitability, leverage, and long-term return data. Mediwound employs 121 people.
For Mediwound, this section uses periodic company reporting and market reference feeds and standardizes the results for cross-period comparison. Analyst projections are included when active coverage applies. Intraday timing differences may exist. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Vlad Skutelnik - Macroaxis ContributorWorkforce Efficiency and Productivity
Investors reviewing Mediwound can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Mediwound Manpower Efficiency
Return on Mediwound Manpower
| Revenue Per Employee | 140.2K | |
| Revenue Per Executive | 1.3M | |
| Net Loss Per Employee | 197.3K | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 283.1K | |
| Working Capital Per Executive | 2.6M |
Popular Tools for Mediwound Stock analysis
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |